Holen Sie sich die Stockscreener-App
4.62
0.65%
-0.03
Handel nachbörslich:
4.58
-0.04
-0.87%
Schlusskurs vom Vortag:
$4.65
Offen:
$4.69
24-Stunden-Volumen:
894.44K
Relative Volume:
0.79
Marktkapitalisierung:
$888.54M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-10.50
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
-3.14%
1M Leistung:
+3.59%
6M Leistung:
+38.32%
1J Leistung:
+37.91%
1-Tages-Spanne:
$4.595
$4.73
1-Wochen-Bereich:
$4.59
$4.995
52-Wochen-Spanne:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.62 | 894.31M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
How sustainable is Arbutus Biopharma Corporation stock dividend payoutBear Alert & Safe Entry Momentum Stock Tips - ulpravda.ru
Why Arbutus Biopharma Corporation stock is popular among millennialsQuarterly Portfolio Summary & Long-Term Growth Plans - ulpravda.ru
New Highs: Why Arbutus Biopharma Corporation stock is popular among millennialsEarnings Miss & Growth-Oriented Investment Plans - ulpravda.ru
What is the fair value of Arbutus Biopharma Corporation stock nowWeekly Trading Summary & Weekly Momentum Picks - ulpravda.ru
Will Arbutus Biopharma Corporation stock deliver shareholder valueWeekly Market Report & Fast Entry Momentum Alerts - ulpravda.ru
How Arbutus Biopharma Corporation stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Momentum Picks - ulpravda.ru
Is Arbutus Biopharma Corporation stock supported by strong fundamentals2025 Pullback Review & Consistent Income Trade Recommendations - ulpravda.ru
Why Arbutus Biopharma Corporation stock is seen as undervaluedProduct Launch & Low Drawdown Trading Strategies - ulpravda.ru
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6%Still a Buy? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Why Arbutus Biopharma Corporation stock is rated strong buyEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
ABUS (Arbutus Biopharma) OCF Margin % : -1,099.62% (As of Sep. 2025) - GuruFocus
Is Arbutus Biopharma Corporation stock ready for breakoutCEO Change & Reliable Entry Point Alerts - ulpravda.ru
Does Arbutus Biopharma Corporation stock trade at a discount to peersPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4%What's Next? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.6%Should You Buy? - MarketBeat
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
[8-K] Arbutus Biopharma Corp Reports Material Event | ABUS SEC FilingForm 8-K - Stock Titan
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
New Haven biotech names new CFO - Hartford Business Journal
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Arbutus Biopharma (ABUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Why Arbutus Biopharma Corporation (I9DN) stock could outperform next yearJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
There is no way Arbutus Biopharma Corp (ABUS) can keep these numbers up - setenews.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
How Arbutus Biopharma Corporation (I9DN) stock reacts to new regulationsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A look into Arbutus Biopharma Corp (ABUS)’s deeper side - Setenews
Why Arbutus Biopharma Corporation stock is trending among retail tradersJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Arbutus Biopharma Corporation stock trend outlook and recovery pathQuarterly Market Summary & Daily Price Action Insights - newser.com
How Arbutus Biopharma Corporation (I9DN) stock compares with market leadersWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
How Arbutus Biopharma Corporation stock compares to growth peersMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital - Defense World
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Big Picture & Reliable Intraday Trade Plans - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital - MarketBeat
What indicators show strength in Arbutus Biopharma Corporation2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
What analysts say about Arbutus Biopharma Corporation I9DN stockBull Market Opportunities & Follow Top Performers in the Community - earlytimes.in
Arbutus Biopharma (ABUS) Receives Steady Buy Rating from Chardan Capital | ABUS Stock News - GuruFocus
Arbutus Biopharma Faces Losses And Legal Battles This Quarter - Finimize
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):